SyrSpend® SF in EDQM document for COVID-19.

Τετ, 01/04/2020

SyrSpend® SF mentioned in EDQM document with possible treatments for COVID-19.

At the moment, there are numerous clinical trials being conducted with an aim to demonstrate the safety and efficacy of different active substances as treatments for COVID-19.
EDQM and the European Paediatric Formulary Working Party (PaedF), issued an advisory document on formulations for active substances used in clinical trials for COVID-19.

Suggested formulation on EDQM is chloroquine phosphate in SyrSpend® SF. Click here to find out more

Consult Fagron Hellas for more information about innovative compounding vehicles, compatibility data, and suggested formulations for antiviral treatment.